Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Recently, expectations have been raised that molecular biological studies of human tumours may be of value in helping to predict future clinical behaviour, in terms of therapeutic response and long-term survival. The epidermal growth factor receptor (EGFr) is a cell surface receptor for EGF and transforming growth factor-alpha which is overexpressed by a number of human tumours. This article principally reviews previous investigations of the role of the epidermal growth factor receptor in bladder cancer and examines methods of detection, the correlation between EGFr status and known prognostic indicators and the value of assessing EGFr status in predicting clinical outcome in patients with bladder cancer. Recent studies of the c-erbB-2 proto-oncogene in bladder cancer and of cell cycling using Ki-67 are included.

Original publication

DOI

10.1159/000282357

Type

Journal article

Journal

Urol Int

Publication Date

1992

Volume

48

Pages

365 - 371

Keywords

Biomarkers, Tumor, Epidermal Growth Factor, Humans, Neoplasm Metastasis, Neoplasm Proteins, Neoplasm Recurrence, Local, Prognosis, Proto-Oncogene Proteins, Receptor, Epidermal Growth Factor, Receptor, ErbB-2, Transforming Growth Factor alpha, Urinary Bladder Neoplasms